Université Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, France.
INSERM, CESP, Cancer and Radiation Team, F-94805 Villejuif, France.
Pediatr Blood Cancer. 2019 Feb;66(2):e27495. doi: 10.1002/pbc.27495. Epub 2018 Oct 21.
Very few previous studies have addressed the question of colorectal cancer (CRC) after childhood cancer treatment. We aimed to quantify the roles of radiation therapy and chemotherapy agents in the occurrence of subsequent CRC.
A nested case-control study was conducted using 36 CRC cases and 140 controls selected from 7032 five-year survivors of the French Childhood Cancer Survivor Study (FCCSS) cohort, treated from 1945 to 2000 in France. The radiation dose-distribution metrics at the site of CRC and doses of individual chemotherapeutic agents were calculated. Conditional logistic regressions were performed to calculate odds ratios (ORs).
Overall, patients who received radiotherapy with estimated dose to colon had a 4.3-fold (95% CI, 1.3-17.6) increased risk for CRC compared with patients who did not receive radiotherapy, after adjustment for chemotherapy. This risk increased to 8.9-fold and 19.3-fold among patients who received radiation doses ranging from 20 to 29.99 Gy and ≥30 Gy, respectively. Our data reported a significantly elevated OR for anthracyclines, after controlling for radiotherapy and MOPP regimen. But, restricted analyses excluding patients who had received ≥30 Gy showed that only radiation doses ranging from 20 to 29.99 Gy produced a significant increase in subsequent CRC risk (OR = 7.8; 95% CI, 1.3-56.0), after controlling for anthracyclines and MOPP regimen.
The risk of subsequent CRC was significantly increased after radiation dose (even < 30 Gy). This novel finding supports the need to update monitoring guidelines for CRC to optimize the long-term follow-up for subsequent CRC in survivors of childhood cancer.
很少有研究探讨儿童癌症治疗后结直肠癌(CRC)的问题。我们旨在量化放疗和化疗药物在随后发生 CRC 中的作用。
使用法国儿童癌症幸存者研究(FCCSS)队列中 7032 名五年幸存者中选择的 36 例 CRC 病例和 140 例对照进行了嵌套病例对照研究,这些患者于 1945 年至 2000 年在法国接受治疗。计算了 CRC 部位的放射剂量分布指标和单个化疗药物的剂量。进行了条件逻辑回归以计算比值比(OR)。
总体而言,与未接受放疗的患者相比,接受估计剂量至结肠放疗的患者 CRC 的风险增加了 4.3 倍(95%CI,1.3-17.6),调整化疗后风险增加至 8.9 倍和 19.3 倍。我们的数据报告称,在控制放疗和 MOPP 方案后,蒽环类药物的 OR 显著升高。但是,排除接受≥30Gy 照射的患者的受限分析表明,仅在 20-29.99Gy 范围内的辐射剂量会导致随后 CRC 风险显著增加(OR=7.8;95%CI,1.3-56.0),在控制蒽环类药物和 MOPP 方案后。
即使接受的剂量小于 30Gy,随后发生 CRC 的风险也会显著增加。这一新发现支持更新 CRC 监测指南的必要性,以优化儿童癌症幸存者后续 CRC 的长期随访。